# Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT04649073** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 11 (actual)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **BIOLOGICAL:** OPC-415

## Key facts

- **NCT ID:** NCT04649073
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-18
- **Primary completion:** 2025-04-09
- **Final completion:** 2041-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649073, "Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04649073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*